Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Amgen Stock Gains on Successful Dazodalibep Trial Results

Guavy AI Editorial Team
Instruments
AMGN
Share

Amgen Inc (NASDAQ: AMGN) saw its stock price surge in premarket trading after announcing successful Phase 3 trial results for dazodalibep, a novel treatment targeting Sjögren's disease.

The drug candidate demonstrated a significant improvement in the European Sjögren's Syndrome Disease Activity Index (ESSDAI) as early as Week 4, with safety data showing manageable adverse events and low discontinuation rates.

Amgen plans to present detailed trial results at an upcoming medical conference, which could further validate the drug's commercial prospects.

More on Stocks

Stocks just now

Amazon and Palantir Drive AI Market Growth with Robust Projections

Stocks just now

Amazon Stock Holds Above $254 as Earnings Exceed Expectations

Stocks 2m ago

Cyprus Demands Faster Progress on Aphrodite Gas Field Development

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy